Education
About Us
Working with TipRanks
Follow Us
Kronos Bio, Inc. (KRON)
NASDAQ:KRON
KRON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.65 - $1.60
Previous CloseN/A
Volume122.28K
Average Volume (3M)1.03M
Market Cap
$53.65M
Enterprise Value$46.16M
Total Cash (Recent Filing)$99.73M
Total Debt (Recent Filing)$24.09M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding60,969,000
10 Day Avg. Volume581,768
30 Day Avg. Volume1,026,605
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-1.00
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue1.24
Enterprise Value/Gross Profit5.02
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$1.00Price Target Upside13.64% Upside
Rating ConsensusHold
Number of Analyst Covering0
Kronos Bio News
PremiumCompany Announcements
Kronos Bio Completes Merger with Concentra Biosciences
PremiumCompany Announcements
Kronos Bio Terminates Cambridge Lease Agreement
PremiumCompany Announcements
Kronos Bio Announces Merger with Concentra Biosciences
PremiumCompany Announcements
Kronos Bio Announces Lease Termination AgreementBulls Say, Bears Say
Bulls Say
New Development CandidateKronos announced the nomination of KB-9798 as a development candidate for Sjogren's disease, initiating IND-enabling studies.
Preclinical DevelopmentsKronos is conducting IND-enabling studies for KB-9558 and expects to be IND-ready by the end of 2024, with potential therapeutic roles in HPV-driven cancers.
Strategic PlanningKronos plans to implement significant expense reduction strategies while it explores potential avenues to maximize stakeholder value including acquisitions, mergers, or sales of assets.
Bears Say
Clinical DevelopmentKronos is discontinuing development of istisociclib (KB-0742) due to CNS AEs in ovarian cancer patients.
Safety ConcernsOut of 7 enrolled PROC patients, 5 exhibited neurological events ranging from Grade 1-3 in severity, with 3 discontinuing treatment.
Ownership Overview
27.02% Insiders
3.99% Mutual Funds
17.99% Other Institutional Investors
96.01% Public Companies and
Individual Investors
KRON FAQ
What was Kronos Bio, Inc.’s price range in the past 12 months?
Kronos Bio, Inc. lowest stock price was $0.65 and its highest was $1.60 in the past 12 months.
What is Kronos Bio, Inc.’s market cap?
Kronos Bio, Inc.’s market cap is $53.65M.
When is Kronos Bio, Inc.’s upcoming earnings report date?
Kronos Bio, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 11 days.
How were Kronos Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Kronos Bio, Inc. overvalued?
According to Wall Street analysts Kronos Bio, Inc.’s price is currently Undervalued.
Does Kronos Bio, Inc. pay dividends?
Kronos Bio, Inc. does not currently pay dividends.
What is Kronos Bio, Inc.’s EPS estimate?
Kronos Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kronos Bio, Inc. have?
Kronos Bio, Inc. has 60,969,000 shares outstanding.
What happened to Kronos Bio, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kronos Bio, Inc.?
Currently, no hedge funds are holding shares in KRON
Kronos Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (13.64% Upside)
$1.00 (13.64% Upside)
Blogger Sentiment
Bullish
KRON Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.66%
12-Months-Change
Fundamentals
Return on Equity
-59.49%
Trailing 12-Months
Asset Growth
-40.90%
Trailing 12-Months
Company Description
Kronos Bio, Inc.
Kronos Bio, Inc. (KRON) is a biotechnology company dedicated to discovering and developing novel cancer therapeutics. With a focus on targeting dysregulated transcription, Kronos Bio aims to address difficult-to-treat cancers by exploiting transcriptional dependencies. The company's pipeline includes small molecule therapies designed to modulate transcription factors, which are often implicated in cancer progression.
Technical Analysis
Verrica Pharmaceuticals
―
Sutro Biopharma
―
Serina Therapeutics
―
PMV Pharmaceuticals
―
Gain Therapeutics
―